Related Experiment Video

Updated: May 1, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.3K

Immunologic and clinical effects of targeting PD-1 in lung cancer

R D Harvey1

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.

Clinical Pharmacology and Therapeutics
|April 3, 2014
PubMed

Insights

Blocking the programmed cell death protein-1 (PD-1) pathway with antibodies helps T-cells fight cancer. This review covers PD-1 inhibitors for lung cancer, including their development and clinical use.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The programmed cell death protein-1 (PD-1) pathway is a key immune checkpoint that regulates T-cell activity.
  • Inhibiting the PD-1 pathway can restore anti-tumor immune responses, offering a promising strategy for cancer therapy.

Purpose of the Study:

  • To review preclinical evidence and clinical pharmacology of PD-1 blockade for lung cancer.
  • To provide an overview of PD-1 inhibitors in development and their clinical application in lung cancer.

Main Methods:

  • Review of preclinical studies on PD-1 pathway inhibition.
  • Analysis of clinical pharmacology of PD-1 and its ligands.
  • Overview of agents in development and clinical trial data for lung cancer.

Main Results:

  • PD-1 pathway inhibitors have demonstrated significant activity in initial clinical trials for lung cancer.
  • Several therapeutic antibodies targeting PD-1 or its ligands are in various stages of development.

Conclusions:

  • Blockade of the PD-1 pathway represents a significant advancement in lung cancer immunotherapy.
  • Understanding the clinical pharmacology and ongoing development of PD-1 inhibitors is crucial for optimizing their application in lung cancer treatment.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K